| |
Download our guide to learn how to navigate the complex European landscape and gain insights on how late-stage customization could make your European distribution simpler and more efficient. Download now. 
|
|
Today’s Big NewsOct 20, 2023 |
| By Max Bayer Amgen is diving deeper into phase 2 tarlatamab data after teasing the molecule's promise a couple of months ago. The asset is one of a handful of bispecific T-cell engagers that have been a focal point of the pharma's oncology work. |
|
|
|
By Nick Paul Taylor Merck & Co. has secured a seat at the productive Daiichi Sankyo antibody-drug conjugate (ADC) factory. While AstraZeneca picked up the first two ADCs off the production line, its rival and collaborator Merck is paying $4 billion upfront to co-develop Daiichi’s next three prospects. |
By Annalee Armstrong Merck & Co. has signed a multi-billion dollar deal with Daiichi Sankyo to work on ADCs, setting a theme for the Madrid-based ESMO conference. |
Sponsored by Tanvex CDMO Reacting to the growth of biotherapeutics, Tanvex BioPharma USA, Inc., is set to launch Tanvex CDMO, a full-service CDMO specializing in mammalian- and microbial-derived biologics and biosimilars. |
|
Best-in-class thermostability and excellent inhibitor tolerance deliver compatibility across a range of clinically relevant samples and superior results in pathogen detection assays. Lyophilization-friendly formats available. Learn more. .png)
|
|
By Gabrielle Masson Flagship Pioneering’s Senda Biosciences and Laronde are merging into Sail Biomedicines, a new biotech designed to develop programmable medicines with more than $700 million in its combined coffers. |
By Nick Paul Taylor One of the last drugs standing at Johnson & Johnson’s slimmed-down infectious disease unit has come through another test. The oral candidate, JNJ-1802, induced antiviral activity against dengue in a human challenge study, offering J&J encouragement as it works toward data in a larger community-based trial. |
By James Waldron Undeterred by the FDA’s rejection earlier this month, Eli Lilly has posted long-term data demonstrating its atopic dermatitis treatment lebrikizumab can provide sustained skin benefits over two years. |
By Helen Floersh A vaccine designed to target three different strains of potentially lethal coronaviruses, including the one that causes COVID-19, appears to be effective in mice. |
By Max Bayer,Gabrielle Masson British pharma GSK is bringing on a Google DeepMind vet to lead AI/ML work. Y-mAbs names ex-Novartis radiopharma leader as new CEO. CARGO Therapeutics taps Genentech cancer leader to be chief medical officer. |
By Annalee Armstrong If anyone in Spain is wondering where the espresso machines are, they are at the exhibit hall for the European Society for Medical Oncology Congress, where one faces an important question: From which Big Pharma will I accept my complimentary espresso beverage? |
By Angus Liu Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate. |
By Anastassia Gliadkovskaya All Americans with a valid prescription, regardless of their insurance status, can use GoodRx at more than 70,000 retail pharmacies to access a 30-day supply of Lantus for $35. |
By Angus Liu After a boom during the pandemic, sales from COVID-19 drugs are now nonexistent at Roche. But the Swiss pharma’s blood cancer portfolio is enjoying a rejuvenation. |
By Ayla Ellison,Fraiser Kansteiner In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. |
By Zoey Becker The combination of Johnson & Johnson’s Rybrevant and the Yuhan-partnered lazertinib triumphed over AstraZeneca’s Tagrisso in a head-to-head study. Elevar and Hengrui inked a commercialization deal potentially worth more than $600 million. Plus more. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. |
|
|---|
|
|
|
Learn how to improve yield and reproducibility with advanced sample prep for a variety of multiomics use cases, especially for suboptimal biospecimens. See how to get quality results from complex samples thanks to key innovations in ultrasonication. Learn more. 
|
|
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Edison Ballroom, New York City |
|
|
| |
|
